Protalix BioTherapeutics (NYSE:PLX) Given New $15.00 Price Target at HC Wainwright

Protalix BioTherapeutics (NYSE:PLX) had its price target increased by equities researchers at HC Wainwright from $10.00 to $15.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 495.24% from the company’s current price. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.06 EPS.

Separately, StockNews.com lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 24th.

Protalix BioTherapeutics Stock Performance

Shares of PLX opened at $2.52 on Monday. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.54. The firm has a 50 day moving average price of $2.01 and a 200-day moving average price of $1.43. The firm has a market cap of $185.56 million, a price-to-earnings ratio of -19.38 and a beta of 0.75.

Hedge Funds Weigh In On Protalix BioTherapeutics

A number of large investors have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd bought a new position in shares of Protalix BioTherapeutics in the fourth quarter worth approximately $35,000. PFG Investments LLC purchased a new stake in Protalix BioTherapeutics during the 4th quarter valued at $39,000. Cubist Systematic Strategies LLC bought a new stake in Protalix BioTherapeutics in the 2nd quarter worth $37,000. XTX Topco Ltd purchased a new position in shares of Protalix BioTherapeutics in the third quarter valued at about $36,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Protalix BioTherapeutics during the third quarter valued at about $38,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.